Preclinical Development of the Class-I-Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors.
Diamond JR, Pitts TM, Ungermannova D, Nasveschuk CG, Zhang G, Phillips AJ, Bagby SM, Pafford J, Yacob BW, Newton TP, Tentler JJ, Gittleman B, Hartman SJ, DeMattei JA, Winkler JD, Wendt MK, Schiemann WP, Eckhardt SG, Liu X, Piscopio AD.
Diamond JR, et al. Among authors: liu x.
Mol Cancer Ther. 2022 Mar 1;21(3):397-406. doi: 10.1158/1535-7163.MCT-21-0455.
Mol Cancer Ther. 2022.
PMID: 34965958
Free PMC article.